Company intelligence / Profile preview

Samyang Biopharmaceuticals Corporation

Seongnam, Gyeonggi-do, South Koreasamyangbiopharm.com ↗

Ownership: Private
Development stage: Commercial

Overview

Samyang Biopharmaceuticals has successfully commercialized several oncology products including Genexol, Genexol PM, Nanoxel M, and Pemed S. Their pharmaceutical plant has received GMP certifications from regulatory authorities in Europe and Japan.

Therapeutic areas: GastroenterologyOncology
Modalities: Small moleculesPolymeric micellesMonoclonal antibodiesRecombinant proteinsAntibody Drug Conjugates (ADC)Transdermal drug delivery systems
Industry: Biotech

Drug pipeline

8 assets

paclitaxel polymeric micelle

7 more assets in the full pipeline.

Request access →

Partnerships

Collaborations with biotechnology firms, pharmaceutical companies, venture firms, research institutes, and universities

Beyond the preview

Go deeper on Samyang Biopharmaceuticals Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Samyang Biopharmaceuticals Corporation.

Explore the full profile